Information Provided By:
Fly News Breaks for February 10, 2020
Feb 10, 2020 | 06:51 EDT
Mizuho analyst Vamil Divan raised his price target for AbbVie to $104 from $96 and reiterates a Buy rating on the shares. The analyst views the 2020 guidance for the standalone company as encouraging and continues to believe the Allergan acquisition changes the AbbVie story for the better. Despite the stock's 6% rally on Friday and 13% rally last week, Divan continues to see the current valuation as "compelling with a path to further upside."
News For ABBV From the Last 2 Days
There are no results for your query ABBV